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Edited by Jesus AvilaAbstract Promyelocytic leukemia zinc ﬁnger protein (PLZF) is
a sequence-speciﬁc, DNA binding, transcriptional repressor dif-
ferentially expressed during embryogenesis and in adult tissues.
PLZF is known to be a negative regulator of cell cycle progres-
sion. We used PLZF as bait in a yeast two-hybrid screen with a
cDNA library from the human ovary tissue. A novel cervical can-
cer suppressor 3 (CCS-3) was identiﬁed as a PLZF interacting
partner. Further characterization revealed the BTB domain as
an interacting domain of PLZF. Interaction of CCS-3 with
PLZF in mammalian cells was also conﬁrmed by co-immunopre-
cipitation and in vitro binding assays. It was found that, although
CCS-3 shares similar homology with eEF1A, the study deter-
mined CCS-3 to be an isoform. CCS-3 was observed to be down-
regulated in human cervical cell lines as well as in cervical tumors
when compared to those from normal tissues. Overexpression of
CCS-3 in human cervical cell lines inhibits cell growth by induc-
ing apoptosis and suppressing human cyclin A2 promoter activ-
ity. These combined results suggest that the potential tumor
suppressor activity of CCS-3 may be mediated by its interaction
with PLZF.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Promyelocytic leukemia zinc ﬁnger protein (PLZF) is a se-
quence-speciﬁc DNAbinding protein containing nine C-termi-
nal C2H2 zinc ﬁnger motifs and an N-terminal BTB (broad
complex, tramtrack, bric-a-brac)/POZ (Pox virus and zinc ﬁn-
ger) [1–4]. PLZF functions as a transcriptional regulator for
cell cycle progression by binding to the promoter of target
genes, such as those for cyclin A and the interleukin-3 receptor
a subunit [5–8]. It also interacts with nuclear co-repressor pro-Abbreviations: CCS-3, cervical cancer suppressor 3; PLZF, promy-
elocytic leukemia zinc ﬁnger protein; BTB, broad complex tramtrack
bric-a-brac; Sp1, speciﬁcity protein 1; Bcl-6, B-cell lymphoma 6;
ONPG, O-nitrophenyl b-D-galactopyranoside; FITC, annexin
V-ﬂuorescein isothiocyanate; PI, propidium iodide
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doi:10.1016/j.febslet.2006.06.047teins such as N-CoR, SMRT, and mSin3A, which in turn
interact with histone deacetylases (HDAC1) [9–12].
PLZF is expressed during early embryogenesis of the axial
skeleton, liver, and heart. It serves as a regulator for Hox gene
expression, which is utilized as a growth-inhibitor and pro-
apoptotic factor in limb budding. In the hematopoietic system,
PLZF is expressed in bone marrow, early myeloid cell lines,
and peripheral blood mononuclear cells, as well as in the
ovary, and at lower levels, in the kidney and lungs [5,13].
The BTB/POZ domain of PLZF is an evolutionarily con-
served protein–protein interaction domain found in essential
transcriptional regulators involved in a variety of important
developmental processes, such as in homeostasis, neoplasia,
apoptosis, cell growth, proliferation, diﬀerentiation, nuclear
sub-localization, and transcriptional repression during pattern
formation in embryogenesis [14–21]. The BTB/POZ domain is
also strongly implicated in the regulation of gene expression
through the local chromatin conformation. The BTB/POZ mo-
tif, downregulates transcription by interacting with speciﬁcity
protein 1 (Sp1) zinc ﬁnger and by also interfering with DNA
binding activity of Sp1 [22]. Another BTB/POZ protein, B-cell
lymphoma 6 (Bcl-6), is rearranged in a large diﬀuse cell known
as Hodgkin’s lymphoma, as well as in AIDS-associated lym-
phoma, and is also upregulated during myogenesis [23–25].
These reports suggest a critical role played by the BTB/POZ
motif.
To begin to characterize the PLZF-dependent pathway, we
used a yeast two-hybrid system to screen a human ovary cDNA
library for novel PLZF binding proteins. We identiﬁed human
cervical cancer suppressor 3 (CCS-3), a component of cervical
tumor suppression. CCS-3 was found to have similarities to
eukaryotic elongation factor 1A (eEF1A) which is implemented
in cellular processes including the organization of cytoskeleton,
oncogenic transformation, signal transduction, and nuclear ex-
port of tRNA [26–28]. The mapping studies reveal the BTB do-
main as being a PLZF interacting domain. Overexpression of
CCS-3 and PLZF in human cervical cell lines inhibits cell
growth by inducing apoptosis as well as suppressing the pro-
moter activity of human cyclin A2. These results suggest that
the cell cycle arrest function of CCS-3 may be involved as a
tumor suppressor for cervical tumors.2. Materials and methods
2.1. Yeast two-hybrid analysis
We constructed the LexA-human PLZF fusion protein and used it as
bait to screen the binding proteins from the human ovary cDNA
library in which proteins were expressed as B42 fusion proteins. Theation of European Biochemical Societies.
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EGY48 [MATa, his3, trp1, ura3-52, leu2::pLeu2-LexAop6/pSH18-34
(LexAop-lacZ reporter)] by a modiﬁed lithium acetate method [29].
The cDNAs encoding B42 fusion proteins were introduced into com-
petent yeast cells that already contained pLexA-PLZF and the trans-
formants, tryptophan prototrophy (plasmid marker), were selected
for on a synthetic medium (Ura, His, Trp) containing 2% glucose.
We tested their interactions with pLexA-PLZF on medium containing
5-bromo-4-chloro-3-indolyl-b-D-galactoside as described. Then, b-
galactosidase activity was measured by adding 140 ll of 4 mg/ml O-
nitrophenyl b-D-galactopyranoside (ONPG) [30,31].
2.2. In vitro pull-down assay
cDNA encoding human PLZF was subcloned into the EcoRI and
XhoI restriction sites of the pGEX4T-1 (Amersham Biosciences, Upp-
sala, Sweden) to generate glutathione S-transferase (GST) fusion pro-
tein (GST-PLZF). The human CCS-3 was ligated into pET29a
(Novagen, Madison, WI) using EcoRI and XhoI to generate a histidine
fusion protein (His-CCS-3). GST and histidine fusion proteins were
puriﬁed using either a GST column (Amersham) or a Ni2+ column
(Invitrogen Life Technologies, Carlsbad, CA) according to the manu-
facturer’s protocols. The puriﬁed GST-PLZF (2 lg) was mixed with
His-CCS-3 (2 lg). The mixtures were then added to 20 lg of GST col-
umn matrix (glutathione sepharose 4B) and incubated at 25 C for
30 min. The slurry was pelleted by centrifugation and washed. The pel-
let of the gel matrix was re-suspended in 20 ll elution buﬀer (10 mM
glutathione, 50 mM Tris–HCl, pH 8.0) and incubated at 25 C for
20 min to elute the bound GST fusion proteins. The eluted proteins
were separated by SDS–PAGE and the proteins were detected by Coo-
massie staining.
2.3. Subcloning of deletion mutants of PLZF
Three deletion mutants (BTB domain) of PLZF were isolated by





CGGGAATTCAGCTACATCTGCAGTGAG-30; PLZF(ZF)-R3, 5 0-
ATTCTCGAGTCACACATAGCACAGGTA-3 0. PCR products
spanning each fragment were cloned into the EcoRI and XhoI
restriction sites of the pGilda. Each constructed plasmid was
introduced into yeast EGY48 expressing either CCS-3 or PLZF hybrid
protein.
2.4. Co-immunoprecipitation
cDNA encoding human PLZF was isolated by PCR using a speciﬁc
template which was then cloned into pEGFPC1 (Clontech) and di-
gested with BglII and EcoRI (pEGFPC1-PLZF). The human CCS-3
cDNA was ligated into pcDNA4/HisMax (Invitrogen) using EcoRI
and XhoI (pcDNA4/HisMax-CCS-3). For co-immunoprecipitation,
SiHa cancer cells were co-transfected with the cDNA constructs of
pEGFPC1-PLZF and pcDNA4/HisMax-CCS-3 using FuGENE6
(Roche Applied Science, Basel, Switzerland). As a negative control,
pEGFPC1-PLZF and an empty vector pcDNA4/HisMax was also
co-transfected. Three days after transfection, cells were harvested by
trypsinization and centrifugation. Cell pellets were washed in PBS,
re-suspended in cell lysis solution (50 mM Tris, pH 7.2, 150 mM NaCl,
1% Triton X-100, 1 lg/ml leupeptin, 1 lg/ml pepstatin, 2 lg/ml aproti-
nin, and 200 lg/ml PMSF). Lysates were incubated with anti-GFP
antibody (Zymed) and precipitated with protein A–agarose. The pre-
cipitated proteins were resolved by SDS–PAGE, and determined using
the ECL system (Amersham).2.5. RT-PCR
The normal cells consisted of MRC-5 and IMR-90, which are de-
rived from the ﬁbroblasts cell line. Also included as a normal cell,
HEK-293, which belongs to the human embryonic kidney cell line.
SiHa and HeLa, cervical cancer cells, which originated from the hu-
man cervical cancer lines, were used for the study. A total of 8 patients
with cervical carcinoma were treated in the Department of Obstetrics
and Gynecology, Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, Korea. The cervical carcinoma tissuesbeing studied are squamous carcinomas. After cell lysis with TRIZOL
Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA), the
cell extracts were incubated, with the addition of chloroform, for
5 min at 30 C. After vortexing, the mixtures were centrifuged at
14000 rpm for 15 min. We collected the upper layer and added isopro-
panol for RNA precipitation. After washing with 100% ethanol, 1 lg
of RNA dissolved in distilled water was used. cDNA was prepared
by random priming 500 ng of total RNA using a ﬁrst-strand cDNA
Synthesis kit and then carried out with speciﬁc primers for CCS-3. Fur-
thermore, the PCR product sequences were analyzed, and were found
to be identical to the sequences of the CCS-3 and non-CCS-3 gene,
respectively.2.6. MTT assays
The relative rate of cell proliferation was quantiﬁed by MTT assays.
Brieﬂy, SiHa cervical cancer cells were grown in a DMEM medium
containing 10% FBS. Cells were seeded at a density of 3 · 103 cells
per well on 96-well plates. Three days after transfection, fresh medium
containing 10% FBS, 20 ll of 3-(4,5-dimethylthiazol-2-yl)-2.5-diphe-
nyl-2H-tetrazolium bromide (MTT) solution (Sigma, 5 lg/ml) were
added to each well. Each well was then incubated for an additional
4 h at 37 C. The amount of MTT-formazan was determined through
absorbance using a microculture plate reader at 540 nm. Each sample
was assayed in triplicate and independent experiments were repeated
three times.
2.7. Apoptosis assays
SiHa cervical cancer cells were plated onto 4-chamber slides and then
transfected with Mock (an expression vector only without insert) or
CCS-3 cDNAs for 24 h using Eﬀectene as described above. Cells were
incubated with FITC-labeled Annexin V and propidium iodide (PI)
for 15 min according to the supplier’s protocol (Boehringer Mannheim,
Mannhein, Germany) and then analyzed on a FACS Vantage (Becton
Dickinson, San Jose, USA). For the evaluation of nuclear morphology,
cells were ﬁxed in methanol and stained with 2 lg/ml of DAPI (Boeh-
ringer Mannheim) at 37 C for 15 min, and were washed twice with
PBS and examined with the ﬂuorescence microscope.
2.8. Cell cycle analysis
SiHa cells transfected with Mock or CCS-3 expression vector was
ﬁxed with ice-cold 70% ethanol, centrifuged for 5 min at 1000 · g,
and re-suspended in PBS containing 5 mM EDTA and RNase A
(50 lg/ml). After incubation for 30 min at 37 C, the cells were stained
with PI (50 lg/ml) and analyzed by ﬂow cytometry with FACS.
2.9. Luciferase reporter gene assays
All construct (IL-3R-Luc and pCyclinA2-Luc) for the promoter-re-
porter assay were kindly provided by Dr. Inpyo Choi (Korea Research
Institute of Bioscience and Biotechnology, Taejon, Republic of Korea)
[32]. SiHa cells plated on 60-mm dishes were transfected with the indi-
cated plasmids using Eﬀectene (Qiagen, Hilden, Germany). After lysis,
the cell extracts were incubated with the luciferase substrate for 30 min
at room temperature. Then, a 5 ll aliquot of each sample was trans-
ferred into the luminometer plate, and the luciferase activity was mea-
sured with the Luciferase Assay Systems (promega, Madison, WI,
USA).3. Results
3.1. Identiﬁcation of CCS-3 as a PLZF binding protein and
mapping of the interaction region
The human ovary cDNA library, fused to the gene for the
transcription activator pJG4-5, was introduced into yeast cells
containing pLexA-PLZF as bait. Approximately 3.9 · 106
independent transformants were pooled and re-spread on the
selection media (Ura, His, Trp, Leu) containing 2% galac-
tose to induce the expression of cDNA. If a B42-tagged protein
interacts with PLZF, it will activate the transcription of
the LEU2 gene and allow the host cells to grow on a synthetic
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the selection media, a total of 6 colonies showed galactose
dependency. The plasmids were isolated from the selected yeast
cells and were then introduced into Escherichia coliKC8 to iso-
late the plasmids carrying pJG4-5-cDNA inserts. The plasmids
were then isolated by the plasmid marker trp in the E. coli host,
and the puriﬁed plasmids were sequenced. A homology search
in GenBank using the BLAST program revealed that all six
plasmids encoded CCS-3 (GenBank Accession No. AF322220).
To identify the CCS-3 binding region of PLZF, cDNA con-
structs containing three PLZF deletion mutants were designed
as shown in Fig. 1A. In the two-hybrid system, the full-length
human CCS-3 cDNA and either a plasmid containing a full-
length human PLZF cDNA (Full, Fig. 1A) or a plasmid con-
taining three truncated mutant forms (BTB, RD2, and ZF,
Fig. 1A) of cDNAs were co-transformed into EGY48 yeast
cells. Cells containing only full-length PLZF cDNA construct
and BTB-PLZF grew on the Ura, His, Trp and Leu deﬁcient
plates, whereas yeast cells transformed with both deletion mu-
tant colonies (RD2, and ZF) failed to grow (Fig. 1A). To con-
ﬁrm these results, we determined the binding activity of these
constructs by measuring the relative expression level of b-
galactosidase. As shown in Fig. 1A, b-galactosidase assay re-
sults conﬁrmed that these mutants (RD2, and ZF) could not
bind to CCS-3.
The interaction between PLZF and CCS-3 was further
examined by GST pull-down analysis and co-immunoprecipi-
tation. For GST pull-down analysis, the GST-PLZF fusion
protein was mixed with His-CCS-3, and the mixture was thenFig. 1. PLZF interacts with CCS-3. (A) The structure is a representation of P
for interaction with CCS-3 by two-hybrid assay. The positive interactions wer
of binding strength by ONPG assays to measure the levels of b-galactosidase
in vitro binding assay. The GST-PLZF(full) and GST-PLZF(BTB) fusion p
glutathione aﬃnity puriﬁcation. (C) Co-immunoprecipitation PLZF with C
only) co-transfectant; lane 2, lysate from pEGFPC1-PLZF and pCDNA/His-
immunoblotting with indicated antibodies.puriﬁed employing the GST column matrix. The eluted pro-
teins were separated by gel electrophoresis and the proteins
were detected by Coomassie staining. As shown in Fig. 1B,
GST-PLZF was co-puriﬁed with His-CCS-3 at an approximate
molar ratio of 1:1. As positive controls, GST only (lane 1),
GST-PLZF-Full (lane 2), GST-PLZF-BTB (lane 3), and His-
CCS-3 (lane 4) were puriﬁed using either a GST column matrix
or a Ni2+ column and loaded each 200 ng on the gel. For
co-immunoprecipitation, cDNA constructs of PLZF (pEG-
FPC1-PLZF) and CCS-3 (pcDNA4/HisMax-CCS-3), or pEG-
FPC1-PLZF and pcDNA4/HisMax (vector only) were
co-transfected into SiHa cells. Subsequently, immunoprecipita-
tion was performed using anti-GFP antibody with lysates from
both transfected cells. After immunoprecipitation, the precipi-
tated proteins were immunoblotted using anti-His antibody or
anti-PLZF antibody. As shown in Fig. 1C, pcDNA4/HisMax-
CCS-3 was co-immunoprecipitated with pEGFPC1-PLZF
(lane 2 in upper panel), whereas no interaction was observed be-
tween pcDNA4/HisMax (vector only) and pEGFPC1-PLZF
(lane 1 in upper panel). An immunoblotting using anti-PLZF
antibody conﬁrmed that an equal amount of PLZF was precip-
itated in both samples (middle panel). Whole cell lysates from
both samples were contained the equivalent proteins when we
immunoblotted using anti b-actin antibody (lower panel).
3.2. Sequence comparison of CCS-3
Due to the lack of information on CCS-3, we identiﬁed the
amino acid sequence of CCS-3, and performed an amino acid
alignment with the NCBI database (Fig. 2A). With the ﬁndings,LZF. Identiﬁcation of the binding domain of PLZF that is responsible
e determined by cell growth on leucine-depleted medium. Quantitation
activity. (B) Interaction between PLZF and CCS-3 were conﬁrmed by
roteins were mixed with His-CCS-3. The mixtures were subjected to
CS-3. Lane 1, lysate from pEGFPC1-PLZF and pCDNA/His (vector
CCS-3 co-transfectant. IP means immunoprecipitation and WB means
Fig. 2. Alignment of CCS-3. (A) Alignment of amino acid sequence of the CCS-3 with H. sapiens eEF1A. (B) The diﬀerences between the two were
found using co-immunoprecipitation analysis, where CCS-3 0s N-terminal region appeared to contain a 101 amino acid deletion when compared to
eEF1A. (C) Western blot analysis of eEF1A or CCS-3 in human HEK 293 and MRC-5. Lane 1, lysate from HEK 293 (normal human embryonic
kidney cell lines); lane 2, lysate from MRC-5 (normal ﬁbroblasts cell lines). Western blot analysis was conducted by employing eEF1A polyclonal
antibody, which has 163–462 amino acids corresponding to an epitope at its C-terminus.
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homology. The diﬀerences between the two were found using
co-immunoprecipitation analysis, where CCS-3 0s N-terminal
region appeared to contain a 101 amino acid deletion when
compared to eEF1A. We believe the 101 amino acids that do
not appear on CCS-3 are the amino acids that produce eEF1A’s
functions. Since eEF1A and CCS-3 conduct opposite functions,
more research must be conducted on the N-terminal regions of
both in order to formulate function and mechanism (Fig. 2B).
In order to identify whether CCS-3 is an isoform of eEF1A, the
use of the cell lines HEK 293, human embryonic kidney cell,
and MRC-5 were observed through western blotting. Western
analysis was conducted by employing eEF1A polyclonal anti-
body, because this antibody contains 163–462 amino acids cor-
responding to an epitope at its C-terminus. As seen in Fig. 2C,
two bands were identiﬁed, the top being eEF1A and the bottom
being the detection of a smaller protein. Through the results
found we were able to determine that eEF1A was not a partial
cDNA clone, but instead was found to be an isoform, with a
deletion of 101 amino acids at the N-terminal end of eEF1A.
3.3. CCS-3 gene expression
To examine the expression of CCS-3, total RNA was used to
determine the level of CCS-3 expression. Total RNA was iso-
lated from several cervical cells from both normal and tumor
tissues. In contrast to the high level of CCS-3 mRNA in nor-
mal human cell lines (HEK293, MRC5, IMR90), CCS-3
mRNA level was very low to undetectable in human cervical
cancer cells (SiHa, HeLa) (Fig. 3A). From the analyses of 8
diﬀerent patient samples, we also observed the cancer-speciﬁc
reduction of CCS-3 in 7 cases (Fig. 3B and data not shown).All of these results suggest that low CCS-3 expression may
be associated with human cervical cancer.
3.4. CCS-3 induces apoptosis in human cancer cells
To investigate the eﬀects of CCS-3 in human cancer cells,
CCS-3 overexpression was induced in SiHa cervical cancer
cells. Transient overexpression of CCS-3 caused a change in
cell morphology (Fig. 4A) and dramatically reduced in cell
growth (Fig. 4B). To conﬁrm that the reduction in cell num-
bers represented apoptosis, we examined the morphology of
the DAPI-stained nuclei in SiHa cells overexpressing control
vector and full-length CCS-3. Full-length, CCS-3-over-
expressing cells showed fragmented nuclei, which are charac-
teristic of apoptosis, transfectants containing only control
vector did not show any signs of DNA fragmentation
(Fig. 4C). Apoptosis was also examined by FACS analysis
after double staining with Annexin V-ﬂuorescein isothiocya-
nate (FITC) and PI. CCS-3-overexpressing cells showed strik-
ingly similar characteristics of apoptotic cells, notably a low
forward scatter and high side scatter proﬁle (Fig. 4D). In
the control vector culture, 93.31% of the cells were viable,
while 2.84% were in early apoptosis and 3.85% were in the
late or ﬁnal stages of apoptosis (P < 0.01) (left panel). Initial
analysis of the SiHa cells induced with CCS-3 during 12 and
24 h showed no signiﬁcant modiﬁcations in relation to the
control culture (data not shown). However, in SiHa cells trea-
ted with CCS-3 during 72 h, 48.52% of the cells were viable,
while 37.39% were in early apoptosis and 14.09% were in the
late or ﬁnal stages of apoptosis (right panel). These results
suggest that CCS-3 overexpression induce apoptosis in cervi-
cal carcinoma cells.
Fig. 3. Expression of CCS-3 in human cancer cell lines and patient
tissues. (A) RT-PCR was employed, to examine by semi-quantitative
analysis, the expression level of CCS-3 in diﬀerent normal (HEK293,
MRC5, IMR90) and cervical cancer cell lines (SiHa, HeLa). (B) The
expression status of CCS-3 in the normal and cancerous regions was
isolated from human cervical cancer patients. Total RNAs were
isolated from the normal and cancer regions in the patient’s cervix, and
RT-PCR was conducted to compare the CCS-3 expression levels using
speciﬁc primers for CCS-3. Among the eight informative samples, the
results of only four cases are shown. The b-actin cDNA probe was
used to evaluate the amount of mRNA loaded in each lane.
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To explore the functional relation between the interactions
of CCS-3 and PLZF in transcriptional activity, we performed
a luciferase assay with a reporter construct (pIL-3-Luc) con-
taining four copies of the PLZF binding site. We found that
CCS-3 speciﬁcally repressed this reporter gene about twofold
(Fig. 5A). The transcriptional repression was dependent onFig. 4. CCS-3 induces apoptosis in human cancer cells. (A) Cells were t
morphology was observed by light microscopy. (B) Cell growth was determin
SiHa cells. (C) SiHa cells transfected with the indicated expression vectors
ﬂuorescence microscopy. Arrows indicate the observed DNA fragmentations.
cells with the indicated expression vectors were incubated with FITC-label
represent means ± S.D. from at least three independent experiments. *, P < 0the amount of plasmid transfected, and when both CCS-3
and PLZF were expressed, there was an additive eﬀect on
repression (Fig. 5B). Cyclin A2 expression is essential for cell
cycle progression in both normal and cancer cells. CCS-3 also
suppressed the promoter activity of human cyclin A2 which
embraces the PLZF-response factors (Fig. 5C). In addition,
when SiHa cells were treated with TGF-b1, the activity of cy-
clin A2 promoter was decreased, while the expression of CCS-3
and PLZF was increased (Fig. 5D). These combined results
suggest that CCS-3 functions as a transcriptional repressor
and is required for the transcriptional eﬀects of PLZF.4. Discussion
Tumor transformation arises as a result of an accumulation
of genetic and epigenetic alterations to proto-oncogenes and tu-
mor suppressor genes. The genes that are altered during tumor-
igenesis chieﬂy aﬀect a variety of biologic pathways such as
apoptosis, cell-cycle, and the diﬀerentiation of the cancer cells
[32–34]. In particular, one ormore factors in the pRb regulatory
pathway, including p53, p16, cyclin D, or pRb itself, may be
inactivated in almost 50–100% of human tumors [35,36]. For
example, the p53 tumor suppressor gene plays a critical role
in maintaining cellular homeostasis and tumor-free survival
of an organism by modulating cell-cycle progression or apopto-
sis [37,38]. Normal cells and tissues are tightly regulated by the
balance between cellular proliferation and death by extracellu-
lar signals, and this is mediated by the activation of cell-cycle
factors. The diversity of transcription factor oncogenes impli-
cated in the human lymphoma and in leukemia is striking,
although their essential functions can be traced to the funda-
mental steps of cell growth, development, or survival [39].ransfected with control vector or CCS-3 expression vector and cell
ed by MTT colorimetric assay with the indicated expression vectors in
were stained with DAPI to examine the nuclei and then examined by
Size bar, 20 lm. (D) Apoptotic cell death by CCS-3. Transfected SiHa
ed Annexin V and PI for 15 min and then analyzed by FACS. Data
































































































Fig. 5. CCS-3 enhances transcriptional repression mediated by PLZF. (A and B) Dose-dependent transcriptional repression of CCS-3 on the pIL-3-
Luc activity. (C) Dose-dependent transcriptional repression of CCS-3 on the cyclin A2-Luc activity. The indicated amounts (lg) of each plasmid were
transiently transfected in SiHa cells. At 48 h after transfection, the cells were assayed for luciferase activity. Data represent means ± S.D. from at least
three independent experiments. *, P < 0.05; **, P < 0.01 compared with control alone. (D) Eﬀects of TGF-b1/CCS-3 on PLZF activity. SiHa cells
transfected with luciferase-reporter plasmid bearing human cyclin A2 promoter were incubated in the presence of 1.5 ng/ml TGF-b1 for 24 h, and
harvested for luciferase activity (left), for RT-PCR analysis of CCS-3 (right).
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Cys2-His2 zinc ﬁnger motifs related from Drosophila to Homo
sapiens and containing an N-terminal BTB/POZ protein–pro-
tein interaction domain. The domain inhibits the binding of
transcription factors, including RARa, to DNA when linked
cis, suggesting that PLZF-RARa may act by sequestering
RxR or by sequestering other retinoid receptors within inactive
multimeric complexes [1,40]. PLZF is expressed in multiple tis-
sues during early development. It is also expressed by early
hematopoietic progenitor cells with a speckled nuclear distri-
bution and is downregulated during myeloid diﬀerentiation
[13].
The mechanism of transcription repression of PLZF has been
shown to occur via the binding of the sequence-speciﬁc DNA
promoter followed by recruitment of corepressor proteins,
N-coR and SMRT, mSIN3A and HDAC1, members of a
multi-protein complex of histone deacetylases. ETO nuclear
factor interacts with PLZF and can potentiate transcriptional
repression by PLZF [19]. Recently, VDUP1 upregulated by
TGF-b1, was shown to inhibit the cell-cycle by recruiting co-
repressor complex including FAZF, PLZF, and HDAC1 [34].
eEF1A plays many important roles in eukaryotic cells aside
from its central role of translation. eEF1A forms complexes
with other components of the cell such as actin and tubulin
[26,41,42]. The role of EF1A in oncogenesis has been investi-gated in prostate carcinoma as well [43]. Also, it has been
shown that eEF1A protein is over-expressed in metastatic cells
as compared to non-metastatic cells, and eEF1A from meta-
static cells contain a lower aﬃnity for F-actin [44]. The impor-
tance of eEF1A in our research lies in eEF1A’s reported ability
to be involved in apoptosis. eEF1A expression is upregulated
by p53 transcription factor when located in erythroleukemic
cell lines of an apoptotic phenotype expressed only in the tem-
perature sensitive mutant p53 gene [45,46].
In this study, we provided evidence that CCS-3 has anti-tu-
mor activity when associated as a component of transcrip-
tional co-repressors. We have examined the expression
pattern of CCS-3 in various tissue and cell lines. A semi-quan-
titative RT-PCR analysis demonstrated that CCS-3 expression
was dramatically reduced in tumor tissues but not in normal
tissues. We identiﬁed CCS-3, a component of the cervical tu-
mor suppressor, as a novel PLZF binding protein. The interac-
tion between PLZF and CCS-3 could be the ﬁrst example of a
regulation mechanism the PLZF protein, which may have a
role in preventing nuclear translocation of PLZF. Another
important function of CCS-3 is its role in cell cycle regulation.
Overexpression of CCS-3 and PLZF in human cervical cancer
cell lines inhibits cell growth and suppresses cyclin A2 pro-
moter activity. This suppressive eﬀect may be due to the
recruitment of the transcriptional repressor factor. Our result
S.B. Rho et al. / FEBS Letters 580 (2006) 4073–4080 4079on the CCS-3 binding assay with PLZF the yeast two-hybrid
system revealed that the critical PLZF domain for binding
CCS-3 resided within the BTB/POZ domain. The domain is
known as a transcriptional repressor.
In summary, we have identiﬁed CCS-3 as a novel binding
partner for PLZF via yeast two-hybrid screening. We have also
mapped the critical molecular domains required for this inter-
action. Overexpression of CCS-3 in human cervical cell lines
inhibits cell growth by inducing apoptosis and suppressing
human cyclin A2 promoter activity. Transfection experiments
indicate that CCS-3 may bind PLZF and prevent nuclear
translocation. These combined results suggest that the cell
cycle arrest of CCS-3 may be involved in the transcriptional
repression pathway in cervical tumors.
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